Literature DB >> 8795126

Mechanisms of T-type calcium channel blockade by zonisamide.

M Kito1, M Maehara, K Watanabe.   

Abstract

We investigated the effects of zonisamide, a new antiepileptic drug, on voltage-dependent T-type calcium current (ICa) in cultured neuroblastoma cells of human origin (NB-I). Zonisamide reduced T-type ICa in a concentration-dependent manner without evoking any change in its inactivation kinetics or voltage dependence of action. The mean percent reduction was 38.3 +/- 5.8% at 50 microM. Further, zonisamide shifted the inactivation curve approximately 20 mV negative compared to the control. These resting blocking actions suggest that zonisamide shifts the channel population toward the inactivation state, allowing fewer channels to open during membrane depolarization. The blockade of T-type calcium channels by zonisamide could suppress an important component of inward current that underlies epileptiform cellular bursting, thereby inhibiting the spread of seizure activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8795126     DOI: 10.1016/s1059-1311(96)80104-x

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  23 in total

1.  Zonisamide in managing impulse control disorders in Parkinson's disease.

Authors:  Pedro Emilio Bermejo; Cristina Ruiz-Huete; Buenaventura Anciones
Journal:  J Neurol       Date:  2010-05-28       Impact factor: 4.849

Review 2.  Pharmacological Management of the Genetic Generalised Epilepsies in Adolescents and Adults.

Authors:  Linda J Stephen; Martin J Brodie
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

3.  In vivo evaluation of the effect of zonisamide on the hippocampal redox state during kainic acid-induced seizure status in rats.

Authors:  Yuto Ueda; Taku Doi; Jun Tokumaru; Akira Nakajima; Keiko Nagatomo
Journal:  Neurochem Res       Date:  2005-09       Impact factor: 3.996

4.  T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor.

Authors:  Adrian Handforth; Gregg E Homanics; Douglas F Covey; Kathiresan Krishnan; Jae Yeol Lee; Kenji Sakimura; Fredricka C Martin; Arnulfo Quesada
Journal:  Neuropharmacology       Date:  2010-06-12       Impact factor: 5.250

Review 5.  Low threshold T-type calcium channels as targets for novel epilepsy treatments.

Authors:  Kim L Powell; Stuart M Cain; Terrance P Snutch; Terence J O'Brien
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

6.  The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance.

Authors:  Patricia K Sonsalla; Lai-Yoong Wong; Bozena Winnik; Brian Buckley
Journal:  Exp Neurol       Date:  2009-12-04       Impact factor: 5.330

7.  Zonisamide decreases ethanol intake in rats and mice.

Authors:  Clifford M Knapp; Melissa Mercado; Tara Lynn Markley; Steven Crosby; Domenic A Ciraulo; Conan Kornetsky
Journal:  Pharmacol Biochem Behav       Date:  2007-04-11       Impact factor: 3.533

8.  Pharmacometabolomics applied to zonisamide pharmacokinetic parameter prediction.

Authors:  J C Martínez-Ávila; A García Bartolomé; I García; I Dapía; Hoi Y Tong; L Díaz; P Guerra; J Frías; A J Carcás Sansuan; A M Borobia
Journal:  Metabolomics       Date:  2018-05-09       Impact factor: 4.290

9.  Treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy.

Authors:  Stéphane Auvin
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

10.  Zonisamide - a review of experience and use in partial seizures.

Authors:  Angus A Wilfong; L James Willmore
Journal:  Neuropsychiatr Dis Treat       Date:  2006-09       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.